Small molecule inhibitors of EGFR and PI3K
US10206924B2 · kind B2 · utility
6Cited by
4References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 15, 2015 |
| Grant date | Feb 19, 2019 |
| Priority date | — |
| Expiry date | Dec 15, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinazoline structure or a quinoline structure which function as dual inhibitors of EGFR proteins and PI3K proteins, and their use as therapeutics for the treatment of cancer and other diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.